Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR EXON 19 DELETION
(
ENST00000275493.7 )
EGFR EXON 19 DELETION ( ENST00000275493.7 ) - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/880
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/133
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Afatinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23816960
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Afatinib | Sensitivity | true |